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Abstract
Gaucher disease is a lysosomal storage disease caused by mutations in acid b-glucosidase (GCase) leading to defective
hydrolysis and accumulation of its substrates. Two L-type calcium channel (LTCC) blockers—verapamil and diltiazem—have
been reported to modulate endoplasmic reticulum (ER) folding, trafficking, and activity of GCase in human Gaucher disease
fibroblasts. Similarly, these LTCC blockers were tested with cultured skin fibroblasts from homozygous point-mutated GCase
mice (V394L, D409H, D409V, and N370S) with the effect of enhancing of GCase activity. Correspondingly, diltiazem
increased GCase protein and facilitated GCase trafficking to the lysosomes of these cells. The in vivo effects of diltiazem on
GCase were evaluated in mice homozygous wild-type (WT), V394L and D409H. In D409H homozygotes diltiazem (10 mg/kg/
d via drinking water or 50–200 mg/kg/d intraperitoneally) had minor effects on increasing GCase activity in brain and liver
(1.2-fold). Diltiazem treatment (10 mg/kg/d) had essentially no effect on WT and V394L GCase protein or activity levels
(,1.2-fold) in liver. These results show that LTCC blockers had the ex vivo effects of increasing GCase activity and protein in
the mouse fibroblasts, but these effects did not translate into similar changes in vivo even at very high drug doses.
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Introduction
Deficiency of GCase leads to accumulation of its substrates,
glucosylceramide (GC) and glucosylsphingosine (GS), and the
resultant visceral and CNS phenotypes in Gaucher disease [1,2].
Three types of Gaucher disease are clinically delineated, based on
age at recognition and organ involvement. Type 1 is the non-
neuronopathic variant with highly variable visceral disease [2].
Types 2 and 3 have early onset of variable CNS deterioration [1].
About 350 mutations in GCase have been identified in DNAs from
affected patients and many of these are rare or occur in single
families [2]. A mutation with high frequency in the Ashkenazi
Jewish population is N370S. Homozygosity for N370S is
associated with type 1, non-neuropathic disease and variable
visceral involvement [2,3,4]. The L444P recurrent mutation is
highly associated with neuronopathic variants of Gaucher disease,
and is the most common Gaucher disease allele world-wide [2].
The D409H alleles also has significant frequency and homozy-
gotes manifest early onset of variable visceral and the CNS
involvement [5]. Uniquely, calcific aortic root and valve disease
occurs with D409H homozygosity [6]. The V394L allele in
humans has been reported only in the heteroallele state and is
associated with either type 1 or types 2 and 3 depending on the
heteroallele [7]. In contrast to humans, N370S and L444P
homozygosity in mice lead to death within 24 hours [8]. In mice
homozygosity for V394L and D409H leads to defective GCase
activity [8] and survival to .12 mos. with only minor visceral
abnormalities [8].
Currently treatment for Gaucher disease includes enzyme
replacement therapy (ERT) and substrate reduction therapy
(SRT). ERT has significantly improved the health of Gaucher
patients by reversing the visceral disease [9], but it has no effect on
the neuronopathic manifestations due to the insufficient amounts
of enzyme penetrating the blood-brain barrier (BBB) for
therapeutic effect. SRT has been used with patients who cannot
receive ERT, but the therapeutic index of SRT is low, and it is
associated with more side effects [10]. The FDA and EMEA
approved drug for SRT, miglustat, does penetrate the blood brain
barrier [11]. Both ERT and SRT are expensive: .$130,000–
300,000 per year for drug costs alone. Alternative therapies are
needed to access the CNS and reduce the costs.
Small molecules that modulate in vivo or ex vivo GCase stability
or activity have been evaluated recently [12,13]. For selected
GCase variants, a so-called pharmacological chaperone, isofago-
mine (IFG), enhances GCase activity by stabilizing the enzyme in
the ER or enhancing transport of mature GCases into the
lysosome or both [13]. Two LTCC blockers, verapamil and
diltiazem, were reported to affect ER folding, trafficking, and
activity of GCase in fibroblasts from Gaucher disease patients
[12,14]. Here, these LTCC blockers were evaluated in GCase
point mutated mice and derived cells for their effects on GCase
activity in vivo and ex vivo.
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Mouse fibroblasts were from WT, GCase point-mutated mice
(V394L, D409H, and N370S homozygotes, D409V/N370S
compound heterozygotes), and saposin C-deficient (C2/2) plus
V394L homozygotes (4L;C*). These cells were grown to 35%
confluency and incubated in a medium containing diltiazem (0 to
50 mM) for 5 days. The cell lysates were assayed for GCase activity
and protein. GCase activity in V394L, D409H, N370S, C2/2,
and 4L;C* fibroblasts increased $1.5-fold at 50 mM diltiazem in
the dose-response experiments (Fig. 1A). The maximal GCase
enhancements with V394L was achieved at ,6 mM and with
4L;C* at ,12 mM. WT and D409V/N370S fibroblasts showed a
,1.3-fold increase in GCase activity at 50 mM. These maximal
activities for each of the cell strains are displayed as the percentage
of untreated WT levels (Fig. 1C). Relative to untreated WT,
diltiazem-treated mutant cells achieved 13% to 35% of the WT
GCase activity levels. The activities were significantly increased by
1.3- to 2.6-fold compared to untreated cells. Only diltiazem-
treated C2/2 cells achieved WT GCase activity levels.
A second LTCC blocker, verapamil, was tested for its effects on
GCase activities from the same mouse fibroblasts (Fig. 1B). The
GCase activities in verapamil-treated V394L and N370S cells
showed a $1.5-fold activation at 25 mM. WT cells responded to
verapamil with ,1.3-fold enhancement of activity. The other cells
had a #1.3-fold increase in GCase activity. These results indicate
that both WT and variant GCases in mouse fibroblasts responded
to diltiazem and verapamil. Diltiazem had more significant effects
Figure 1. Diltiazem (A) and Verapamil (B) effects on GCase activities in fibroblasts. (A) Fold increase in GCase activities in diltiazem treated
fibroblasts from WT (N), D409H homozygote (9H; %), V394L homozygote (4L; D), N370S homozygote (OS; .), 4L;C* V394L plus C2/2 (4L;C*; #),
(saposin C2/2)( C 2/2; e) and D409V/N370S compound heterozygote (9V/OS; &). (B) Fold increase in GCase activities in verapamil treated
fibroblasts from WT, 9H, 4L, OS, 4L;C*, C2/2 and 9V/OS compound heterozygotes. The cells were incubated in the presence of diltiazem or verapamil
for 5 days. The enhancements of specific GCase activities in treated cells are presented as fold increase relative to the respective untreated cells. (C)
Percentage of untreated WT activity in diltiazem (0 or 50 mM) treated fibroblasts. The GCase activities were significantly increased in treated
fibroblasts. The activities in all treated GCase mutant cells (9H, 4L, OS, 4L;C* and 9V/OS) were below 35% of WT levels. Fold-changes (mean 6 S.E.M) of
diltiazem effects on GCase for each cell line are above the columns. The experiments were done in triplicates. Student’s t test, ***, p,0.001.
doi:10.1371/journal.pone.0007320.g001
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treated GCase mutant were $35% of the WT level.
GCase protein levels and lysosomal localization were deter-
mined in diltiazem-treated V394L, D409H, 4L;C*, C2/2, and
WT cells. GCase protein levels were assessed by immuno blot
analysis using rabbit anti-mouse GCase antibody. Compared to
untreated cells, GCase protein levels were significantly increased
by 1.3- to 1.7-fold in the treated cells with any genotype (Fig. 2).
GCase trafficking to the lysosome was analyzed by colocalization
quantification of fluorescent signals from goat anti-mouse GCase
(FITC, green) and lysosome marker (LysoTracker or Lamp1,
Red). Diltiazem (25 mM) enhanced GCase signals in cells from
WT, V394L, C2/2, and 4L;C* mice (Fig. 3). Pearson’s
correlation coefficients were used to determine the degree of
colocalization of the GCase signals with lysosomal signals (Lyso-
Track or Lamp1) and their change with diltizem treatment. These
coefficients portray the degree of overlap between two images in
FITC and Rhodamine channels and not the level of signals [15],
i.e., values of 0 and 1 indicate no correlation and complete
correlation, respectively. Diltiazem treatment significantly in-
creased Pearson’s correlation coefficients for GCase in WT,
C2/2, D409H, V394L, and 4L;C* cells. The GCases prior to
treatment were localized mostly to the perinuclear regions,
whereas following treatment there were much greater lysosomal
colocalization signals (Fig. 3, Table 1). These results indicate that
diltiazem increases the GCase protein levels and facilitates GCase
trafficking into lysosomes in cultured fibroblasts.
To evaluate the in vivo effects of LTCC blockers on mutant
GCase activity, diltiazem was administered to the mice since its
effects in fibroblast cultures were more significant than those with
verapamil. The doses were determined from the Pediatric Lexi-
Drugs reference and from published studies on rodents [16,17].
WT and GCase point-mutated (V394L and D409H homozygotes)
mice at 4 wks were given diltiazem (10 mg/kg/d) in drinking
water for 4 wks. GCase activities in the brain, lung, spleen, and
liver were analyzed. The harvested tissues from the diltiazem-
treated D409H mice showed a 1.2-fold increase in GCase activity
in the liver relative to those in untreated mice (Fig. 4). V394L liver
GCase activity decreased by 38% after treatment (Fig. 4). No
significant change in GCase activity was detected in the brain,
lung, and spleen of treated D409H and V394L mice or in any
tissues from similarly treated WT mice (Fig. 4). GCase protein
levels in livers from treated WT mice increased by ,1.2-fold
(Fig. 4B). In liver, variable increases (,1.2-fold) in the V394L and
D409H GCase proteins were detected in treated mice (data not
shown).
To ensure drug delivery and effective doses, additional two
studies were conducted for 4 wks. Diltiazem (28 mg/kg/day) via
drinking water was administered to D409H mice, and a higher
dose of diltiazem (44 mg/kg/d) was given to V394L mice. The
GCase activity in the brains and livers of these treated mice were
not significantly altered compared to their untreated genotype-
matched controls (data not shown). Additional D409H mice were
given diltiazem by intraperitoneal injections with 50, 100 or
200 mg/kg/d for 7 days. These doses are ,5–22 times greater
than those (6–9 mg/kg/d) used in hypertensive patients [18]. After
each injection the mice had very slow movements and major
decreases in cage activity for several hours – an indication of
toxicity. Full recovery to normal activity was evident by the next
day. One mouse in the 200 mg/kg/d group died after the second
injection. Small increases of brain GCase activities (,1.2-fold)
were detected in D409H mice receiving 50–200 mg/kg/d (Fig. 5).
The effects on liver D409H GCase activities were minor. GCase
activities were not altered in the lung and spleen of D409H mice
(data not shown).
Discussion
The LTCC blockers diltiazem and verapamil are approved by
the FDA to treat hypertension and cardiac arrhythmias. They
bind to LTCCs on the cell membrane and block calcium influx
that could alter homeostasis in the ER [12,18]. LTCC blockers
enhanced mutant GCase activity and lysosomal targeting in
fibroblasts from individuals with Gaucher disease and were
suggested to have potential therapeutic use [12,14]. The
mechanism of how LTCC blockers alter GCase is not clear, but
they appear to disrupt the unfolded protein response in these cells.
Similar to the findings on human cultured fibroblasts [12,14],
analogous mouse cells carrying GCase point mutations showed
increases in GCase protein and activity, and lysosome localization
when cultured in the presence of diltiazem or varapamil.
Diltiazem exhibited greater enhancements of the WT or mutant
GCases than verapamil. However, neither diltiazem nor verapamil
recovered GCase activity to heterozygote levels in the mutant cells.
Curiously, the WT GCase activity in saposin C-deficient cells was
increased by LTCC blockers. As one of its functions saposin C
protects GCase from protease degradation in the lysosome [19].
Also, diltiazem inhibits the activity of the lysosomal nicotinic acid
adenine dinucleotide phosphate (NADDP)-sensitive calcium re-
lease channel [20]. These findings imply additional effects of
LTCC blockers at the lysosomal level that alter GCase stability
directly in that organelle.
The bioavailability and drug metabolism of diltiazem have been
studied extensively [18] and, importantly, diltiazem penetrates
through the blood brain barrier [21]. In animal models,
intraperitoneal, intravenous injections or oral administration of
diltiazem in doses ranging from 10 to 200 mg/kg/d were effective
Figure 2. GCase protein levels in diltiazem-treated cultured
fibroblasts. (A) Immunoblot of mouse GCase and b-actin protein in
diltiazem (12.5 mM) treated and untreated WT, 4L, 9H, C2/2 and 4L;C*
cell lysates. GCase protein signal levels were increased in the diltiazem-
treated cells. GCase proteins in these fibroblast extracts were detected
using rabbit anti-mouse GCase antibody. b-actin was the loading
control. (B) Fold changes in GCase protein signal levels in diltiazem (Dil)-
treated cells relative to untreated cells. GCase protein levels were
significantly increased in treated cells. Quantitation was performed
using Molecular Dynamics ImageQuant 5.0 Software using the ratio of
GCase/b-actin for normalization. Each experiment was repeated in
triplicate. Fold-changes (mean 6 S.E.M) of diltiazem effects on GCase
for each cell line are above the columns. Student’s t test, ***, p,0.001;
**, p,0.01; *, p,0.05.
doi:10.1371/journal.pone.0007320.g002
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irradiation, and prevention of diastolic heart failure in a familial
hypertrophic cardiomyopathy mouse model [16,22,23]. The doses
of diltiazem used here (10–200 mg/kg/d) were greater than those
used in a clinical setting to treat hypertension (6–9 mg/kg/d) in
humans. At such high doses, the D409H mutant GCase activity
was only incrementally enhanced in vivo.
The success of enzyme therapy (ET) for Gaucher disease has
shifted the phenotype of the nonneuronopathic variant, type 1,
toward normalcy in many patients [9]. However, the inability of
macromolecules, like enzymes, to traverse the blood brain barrier
(BBB) in sufficient amounts so to alter the CNS lysosomal storage
has led to the search for alternative methods of treatment. Several
small molecules have been the focus of interest, because they
penetrate the BBB, modulate protein folding, and/or trafficking of
endogenous mutant enzymes, e.g., GCase, to the lysosomes [12,13].
The majority of these ‘‘chaperones’’ were evaluated in cultured
cells, particularlyfibroblasts from affected individuals [12,24,25,26].
Such ex vivo studies provided data as proof-of-principle and suggest
promise for their use as treatments for the neuronopathic variants of
Gaucher disease. The therapeutic effects of these ‘‘chaperones’’
have not been tested in animal models with residual mutant GCase
activity/protein to provide a physiological foundation for their
potential clinical significance. Here, cells and tissues from our point-
mutated GCase mouse models of GCase defective function were
tested using LTCC blockers as potential therapeutic drugs. As
shown in this study, diltiazem enhanced the activity and lysosomal
trafficking of GCase in cultured fibroblasts from point mutated
mice. In vivo, diltiazem had little if any effect on GCase activity or
protein in WT and V394L mice. D409H fibroblasts had 1.8-fold
enhancement of GCase activity by diltiazem. In D409H homozy-
gous mice, the mutant GCase activity increase (,1.2-fold) was not
dose-dependent. This may be due to diltiazem having reached
maximal effect in vivo at the lowest dose.
Figure 3. Diltiazem treatment increased localization of GCase protein in lysosome. (Top panel) Compared to untreated cells, enhanced
GCase signals (green) in diltiazem (25 mM) treated mouse V394L fibroblasts colocalized with LysoTracker (Red). LysoTracker (Red) fluorescence
intensities were equivalent in both treated and untreated cells. (Bottom panel) Increased D409H GCase (green) expression after diltiazem (25 mM)
treatment was partially localized with Lamp1 (Red), a lysosomal marker. Most of the D409H GCase was localized to the perinuclear region before
treatment. Scatter plots showed colocalization of GCase in the green FITC channel with LysoTracker or Lamp1 in the red Rhodamine channel in the
upper right quadrant (arrow). For lysosome markers, LysoTracker was used for V394L cells and anti-Lamp1 was used for D409H cells.
doi:10.1371/journal.pone.0007320.g003
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of diltiazem on GCase. The factors that contribute to these
differential drug effects may include the effect of LTCC blockers
on dividing (fibroblasts) versus non-dividing cells (neuron), the
penetration efficiency of the drug into the ER (or lysosomes) in
organs versus the cultured cells, and the distribution of LTCCs in
different cell types and organs. The variation in expression of
LTCCs on the membranes of microglial cells and macrophages is
also impacted by various cellular states and microenvironments
[27]. Mice with the most common human Gaucher disease
mutations, N370S and L444P, have early lethality [8,28], and
thus, are not available for these studies. In addition, the alternative
tissue specific knock-out models, the macrophage or neuronal
GCase null mice [29,30], would not be useful for these studies
since residual GCase activity is required for LTCC blockers to
have any effect. However, the D409H mutation is relatively
common in the neuronopathic Gaucher disease variants [2], and,
although rare, V394L has very similar kinetic and cellular
properties, including response to LTCC blockers, as N370S.
Thus, the use of LTCC blockers up to toxic doses in mice with
such GCase mutations appears ineffective in significantly altering
the mutant GCase activity or protein, suggesting that the LTCC
blockers tested here would have no place in the treatment of
individuals with Gaucher disease.
Materials and Methods
Ethics Statement
The mice were maintained in microisolators in accordance with
institutional guidelines under IACUC approval at the Cincinnati
Children’s Hospital Medical Center.
Cell culture and drug treatment
The mouse fibroblasts were derived from WT and point-
mutated GCase mice including homozygotes for V394L, D409H,
and N370S, the compound heterozygous D409V/N370S, homo-
zygous selective saposin C deficiency (C2/2), and combined
homozygotes for V394L and saposin C deficiency (4L;C*). The
fibroblasts were established from the skin of one-day-old pups and
cultured in DMEM with 10% fetal bovine serum, 1% penicillin,
and 1% streptomycin. The cells were seeded at 35% confluence
and incubated with diltiazem hydrochloride (Bedford Laborato-
ries, Bedford, OH) or verapamil (Hospira, INC., Lake Forest, IL)
at series concentrations for 5 days. The cells were harvested for
analysis.
GCase activity assay
The tissues were collected from saline-perfused mice. Fibro-
blasts and tissues were homogenized in 0.25% Triton X-100 and
0.25% sodium taurocholate in citric buffer, pH 5.6. GCase
activities in the tissue and cell lysates were determined as described
with 4-methylumbelliferryl b-D-glucopyranoside (4 MU-Glc,
4 mM) as substrate in 0.25% sodium taurocholate and 0.25%
Triton X-100 [8]. Assay mixtures were preincubated in the
presence and absence of the conduritol B epoxide (CBE, 1 mM), a
specific irreversible inhibitor of GCase, for 30 min at 37uC. The
substrate (4 MU-Glc) was added to the mixture, and incubated for
30 min at 37uC. Protein concentration was determined using the
BCA protein assay reagent.
Immunoblot Analyses
The tissue and cell lysates were prepared as described [31]. The
cell (50 mg) and tissue (200 mg) lysates were resolved on Invitrogen
NuPAGE 4–12% Bis-Tris gel with NuPAGE MED SDS running
buffer and electro-blotted on Hybond
TM-ECL nitrocellulose
membranes. Rabbit anti-mouse GCase (1/1000 in 3% BSA) was
used to detect mouse GCase, and mouse anti-b-actin monoclonal
antibody (1/10,000) was used to detect b-actin. The signals were
developed using an ECL reagent (Amersham Biosciences, Piscat-
away, NJ) according to the manufacturer’s instructions.
Fibroblast Colocalization Studies
Fibroblasts were treated with diltiazem at 25 mM for 5 days.
LysoTracker Red (Molecular probe, L-7528) was applied to the
V394L, WT, C2/2, and 4L;C* cells at 100 nM for 30 min at
37uC. The cells were rinsed with 1x PBS and fixed in 3%
paraformaldhyde for 40 min at room temperature (RT). The fixed
cells were quenched with 50 mM NH4Cl, rinsed with 1x PBS, and
then treated with 0.5% saponin (Sigma, S-7900) and 1% BSA in 1
x PBS for 5 min at RT three times. The cells were incubated with
rabbit anti-mouse GCase IgG (1/100) in 0.5% saponin-PBS, 1%
BSA overnight at 4uC. D409H cells were incubated with rabbit
anti-mouse GCase and rat anti-mouse Lamp1 (DRI, CD107a-
D4B) (1/200) as a lysosome marker. The cells were washed with
0.5% saponin-PBS and labeled with goat anti-rabbit FITC (1/100)
or goat anti-rat Texas red (1/100) for 1 hour at RT. Following a
0.5% saponin-PBS wash, the cells were mounted with mounting
medium containing DAPI (Vector Laboratory). Fluorescence
signals were visualized by Zeiss Axiovert 200 M microscopy
equipped with an Apotome. Pearson’s correlation coefficients were
determined for individual cells using Zeiss Axiovision colocaliza-
tion software. The data was analyzed by Student’s t-test.
Animal care and drug administration
The GCase point-mutated V394L and D409H homozygous
mice were generated as described [8]. The strain background of
V394L and D409H mice was C57BL/6J/129SvEV. WT mice are
in FVB background. Drug administration was started in the mice
at 4 wks of age. The first cohorts (homozygotes for V394L and
D409H, and WT) were given diltiazem via drinking water at
10 mg/kg/d for 4 weeks. The dose in drinking water was
determined using average daily water intake (5 ml) and mouse
weight. The second cohort (D409H) was administered diltiazem
Table 1. Pearson’s correlation coefficients in fibroblasts
treated with diltiazem (25 mM).
Fibroblasts Pearson’s correlation coefficients*
2 Diltiazem + Diltiazem p value
WT 0.60060.031 (n=10) 0.87060.028
(n=13)
,0.0001
V394L/V394L 0.35560.040 (n=11) 0.78560.020
(n=18)
,0.0001
D409H/D409H 0.01760.017 (n=6) 0.48860.038
(n=11)
,0.0001
C2/2 0.52860.033 (n=7) 0.69760.035
(n=10)
,0.0001
4L;C* 0.33760.031 (n=12) 0.81460.020
(n=14)
,0.0001
*, Pearson’s correlation coefficients were determined using Zeiss Axiovision
colocalization software and presented as mean 6 S.E.
Diltiazem treatment significantly increased Pearson’s correlation coefficients,




PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7320Figure 4. GCase protein and activity in diltiazem-treated mice: (A) The 4 wk old mice were administered diltiazem in drinking water (10
mg/kg/day) for 4 wks. D409H livers had ,1.2-fold increases of GCase activity. GCase activity in V394L liver decreased 38% after treatment. No
significant changes in GCase activity were detected in WT, D409H and V394L brain, spleen, and lung. (B) Immunoblot analyses of GCase protein levels
in WT liver. Diltiazem (10 mg/kg/d) increased GCase protein by ,1.2 fold in WT liver. Fold change is presented as the ratio relative to untreated
samples. Quantitation of blots was performed using Molecular Dynamics ImageQuant 5.0 Software and using the ratio of GCase/b-actin for
normalization. Each experiment was repeated in triplicate. n=3 to 7 mice. Student’s t test, **, p,0.01; *, p,0.05.
doi:10.1371/journal.pone.0007320.g004
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PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7320by intraperitoneal injection at three doses: 50, 100, or 200
mg/kg/d for 7 days. The third cohort, included D409H and
V394L homozygotes, was given diltiazem in drinking water for
4 wks at 28 mg/kg/d for D409H homozygotes and 44 mg/kg/d
for V394L homozygotes. The cage activities of the treated mice
were monitored during the study.
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